Tags : Decrease

Sandoz’s Ziextenzo (biosimilar, pegfilgrastim) Receives the US FDA’s Approval to

Shots: The FDA’s approval is based on three-way PK/PD study (LA-EP06-104) assessing Sandoz pegfilgrastim vs US-sourced reference pegfilgrastim, Sandoz pegfilgrastim vs EU-sourced reference pegfilgrastim, and US-sourced vs EU-sourced reference pegfilgrastim demonstrating no differences regarding safety and immunogenicity The addition of long-acting supportive oncology biosimilar will expand Sandoz’s oncology portfolio. Following the approval, Sandoz is the […]Read More